Skip to main content

Main menu

  • Home
  • About
    • JALM
    • Editorial Board
    • Most Read
    • Most Cited
    • Alerts
  • Articles
    • Current Issue
    • Early Release
    • Future Table of Contents
    • Archive
    • Browse by Subject
    • Special Issues & Collections
  • Info for
    • Authors
    • Reviewers
    • Subscribers
    • Advertisers
    • Permissions & Reprints
  • Abstracts
  • JALM Talk
  • Submit
  • Feedback
  • Other Publications
    • Clinical Chemistry

User menu

  • Subscribe
  • My alerts
  • Log in

Search

  • Advanced search
The Journal of Applied Laboratory Medicine
  • Other Publications
    • Clinical Chemistry
  • Subscribe
  • My alerts
  • Log in
The Journal of Applied Laboratory Medicine

Advanced Search

  • Home
  • About
    • JALM
    • Editorial Board
    • Most Read
    • Most Cited
    • Alerts
  • Articles
    • Current Issue
    • Early Release
    • Future Table of Contents
    • Archive
    • Browse by Subject
    • Special Issues & Collections
  • Info for
    • Authors
    • Reviewers
    • Subscribers
    • Advertisers
    • Permissions & Reprints
  • Abstracts
  • JALM Talk
  • Submit
  • Feedback
Research ArticleArticles

Severe Isotype-Matched Immunosuppression (IMI) as a Potential Risk Factor for Progression of MGUS Patients

Juana J. Jiménez, Tiago M. Pais, Nuno Barbosa, Maria Luisa Campos, Maria Antonia Peñalver Díaz, Carmen H. de Larramendi
DOI: 10.1373/jalm.2017.024307 Published February 2018
Juana J. Jiménez
Department of Clinical Chemistry, University Hospital Severo Ochoa, Madrid, Spain;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mandalay1954@gmail.com
Tiago M. Pais
Scientific Department, The Binding Site Iberia, Barcelona, Spain;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nuno Barbosa
Scientific Department, The Binding Site Iberia, Barcelona, Spain;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Luisa Campos
Scientific Department, The Binding Site Iberia, Barcelona, Spain;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Antonia Peñalver Díaz
Department of Haematology, University Hospital Severo Ochoa, Madrid, Spain.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carmen H. de Larramendi
Department of Clinical Chemistry, University Hospital Severo Ochoa, Madrid, Spain;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background: Monoclonal gammopathy of undetermined significance (MGUS) precedes multiple myeloma in virtually every case. However, only a small percentage will progress and at very different rates. In addition, recent data have suggested that MGUS is associated with other comorbidities including infections, suggesting impaired immune function in some MGUS patients. Therefore, we aimed at assessing the value of isotype-matched immunosuppression (IMI; e.g., suppression of an IgAκ in an IgAλ patient), a type of immunosuppression more specific than classical immunoparesis (IP; e.g., IgG and/or IgM suppression in an IgA patient), as a prognostic marker for MGUS progression.

Methods: The Hevylite assay was used to assess IMI and immunoglobulin ratios in 307 serum samples from a cohort of 248 MGUS patients. Follow-up clinical records were available for 154 individuals.

Results: A greater incidence of IMI (51%) over classical IP (37%) was observed, although both show a progressive increase with higher risk groups. Survival analysis of 154 patients showed that severe IMI (>50% suppression) differentiates 2 groups with significantly different time to progression (P = 0.024) while severe IP does not (P = 0.48). Also, a combination of severe IMI and involved monoclonal immunoglobulin >1.5g/dL by Hevylite (both variables found to be independent prognostic markers in multivariate analysis) identified a group of patients with a median time to progression 6-fold shorter than the remaining group (P < 0.0001).

Conclusions: These findings indicate a possible role for IMI in the malignant transformation of MGUS patients and a potential utility as a new risk factor.

Footnotes

  • Authors' Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form.

  • Employment or Leadership: T.M Pais, N.M. Barbosa and M.L. Campos, The Binding Site, Spain. Consultant or Advisory Role: None declared.

  • Stock Ownership: None declared.

  • Honoraria: None declared.

  • Research Funding: None declared.

  • Expert Testimony: None declared.

  • Patents: None declared.

  • Role of Sponsor: The sponsor played a direct role in the preparation and final approval of the manuscript and the choice of enrolled patients.

  • Received June 1, 2017.
  • Accepted September 5, 2017.
  • © 2017 American Association for Clinical Chemistry
View Full Text
PreviousNext
Back to top

In this issue

The Journal of Applied Laboratory Medicine: 2 (5)
Vol. 2, Issue 5
March 2018
  • Table of Contents
  • About the Cover
  • Index by author
Print
Share
Severe Isotype-Matched Immunosuppression (IMI) as a Potential Risk Factor for Progression of MGUS Patients
Juana J. Jiménez, Tiago M. Pais, Nuno Barbosa, Maria Luisa Campos, Maria Antonia Peñalver Díaz, Carmen H. de Larramendi
The Journal of Applied Laboratory Medicine Mar 2018, 2 (5) 700-710; DOI: 10.1373/jalm.2017.024307
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Severe Isotype-Matched Immunosuppression (IMI) as a Potential Risk Factor for Progression of MGUS Patients
Juana J. Jiménez, Tiago M. Pais, Nuno Barbosa, Maria Luisa Campos, Maria Antonia Peñalver Díaz, Carmen H. de Larramendi
The Journal of Applied Laboratory Medicine Mar 2018, 2 (5) 700-710; DOI: 10.1373/jalm.2017.024307

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • METHODOLOGY
    • RESULTS
    • DISCUSSION
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

Articles

  • Europium Nanoparticle-Based Sialyl-Tn Monoclonal Antibody Discriminates Epithelial Ovarian Cancer–Associated CA125 from Benign Sources
  • Comparison of Transcription-Mediated Amplification and Real-Time PCR Assays for Hepatitis B Virus DNA Quantitation in Serum
  • Improving Turnaround Times through a Process Improvement Initiative Involving Barcoding, Floorplans, Dual Measuring Cells, Chemistry Analyzers, and Staff Shifts
Show more Articles

Cancer, Renal, and Other Disease Biomarkers

  • Analytical Characterization of an Enzyme-Linked Immunosorbent Assay for the Measurement of Transforming Growth Factor β1 in Human Plasma
  • Performance of the 4Kscore Test in Plasma and Serum and Stability of the Component Analytes in Clinical Samples
Show more Cancer, Renal, and Other Disease Biomarkers

Similar Articles

Subjects

  • Cancer, Renal, and Other Disease Biomarkers

Navigate

  • Home
  • About
  • Articles
  • Information for Authors
  • Submit

Other Publications

  • Clinical Chemistry
Footer logo

© 2019 American Association for Clinical Chemistry

Powered by HighWire